Improvement effect of ensifentrine-Ohtuvayre on chronic obstructive pulmonary disease

Ensifentine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre, as a new PDE3/PDE4 dual-target inhaled drug, has shown significant efficacy advantages in adult patients with chronic obstructive pulmonary disease (COPD). Its mechanism of action is to simultaneously inhibit PDE3 and PDE4, which can not only relax bronchial smooth muscle, improve airflow restriction, but also reduce airway inflammatory response, thereby comprehensively improving lung function and clinical symptoms. This dual effect is particularly important in patients with moderate to severe COPD, who are often characterized by long-term airway inflammation and reduced respiratory function.

Clinical studies have shown that Ohtuvayre can significantly improve patients’ lung function indicators. The primary efficacy assessment, measured by the area under the FEV1 (forced expiratory volume) concentration-time curve, showed that patients' lung function was significantly better than that of placebo after 12 weeks of treatment. This means that exefantine can improve patients' daily breathing efficiency, reduce symptoms such as shortness of breath and reduced exercise tolerance, thereby improving quality of life. In addition, inhalation administration can directly act on the airway mucosa to maximize local drug efficacy while reducing systemic exposure and reducing the risk of adverse reactions. This is a very important safety advantage in long-term maintenance treatment of COPD.

The application of Ohtuvayre in clinical practice focuses not only on lung function improvement, but also on the control of symptoms and acute exacerbations. Through a dual-target mechanism, it can regulate the airway inflammatory microenvironment, reduce bronchospasm and mucus secretion, and thereby reduce the risk of acute exacerbation. This provides a new long-term management strategy for patients with moderate to severe COPD, and provides a basis for doctors to develop individualized treatment plans.

Overall, exefantine has shown potential advantages in improving lung function, alleviating symptoms and reducing the risk of disease progression through thePDE3/PDE4 dual-target inhibition mechanism. Although it has not yet been launched in China, overseas clinical data provide strong evidence for its scientific application and provide a new maintenance treatment option for patients with COPD.

Reference: https://en.wikipedia.org/wiki/Ensifentrine